Citations

Showing 10 of 108083 citations.

Validation of a Brief Dietary Questionnaire for Use in Clinical Practice: Mini‐EAT (Eating Assessment Tool)
Lara-Breitinger, Kyla , Medina‐Inojosa, José R. , Kunzová, Šárka , Lerman, Amir , Kopecky, Stephen L. , López-Jiménez, Francisco , Li, Zhuo , Lara-Breitinger, Kyla M , Kunzova, Sarka , Lerman, Amir , Kopecky, Stephen L , Lopez-Jimenez, Francisco , Medina-Inojosa, José R , Li, Zhuo

Mayo Clinic

Journal of the American Heart Association | December 30, 2022 | Volume: 12 | Issue: 1 | Pages: No page available

10.1161/jaha.121.025064 | PMID 36583423 Get It

Background There is a scarcity of validated rapid dietary screening tools for patient use in the clinical setting to improve health and reduce cardiovascular risk. The Healthy Eating Index (HEI) 2015 measures compliance with the 2015 to 2020 Dietary Guidelines for Americans but requires completion of an extensive diet assessment to compute, which is time consuming and impractical. The authors hypothesize that a 19‐item dietary survey assessing consumption of common food groups known to affect health will be correlated with the HEI‐2015 assessed by a validated food frequency questionnaire and can be further reduced without affecting validity. Methods and Results A 19‐item Eating Assessment Tool (EAT) of common food groups was created through literature review and expert consensus. A cross‐sectional survey was then conducted in adult participants from a preventive cardiology clinic or cardiac rehabilitation and in healthy volunteers (n=661, mean age, 36 years; 76% women). Participants completed an online 156‐item food frequency questionnaire, which was used to calculate the HEI score using standard methods. The association between each EAT question and HEI group was analyzed by Kruskal‐Wallis test. Linear regression models were subsequently used to identify univariable and multivariable predictors for HEI score for further reduction in the number of items. The final 9‐item model of Mini‐EAT was validated by 5‐fold cross validation. The 19‐item EAT had a strong correlation with the HEI score ( r =0.73) and was subsequently reduced to the 9 items independently predictive of the HEI score: fruits, vegetables, whole grains, refined grains, fish or seafood, legumes/nuts/seeds, low‐fat dairy, high‐fat dairy, and sweets consumption, without affecting the predictive ability of the tool ( r =0.71). Conclusions Mini‐EAT is a 9‐item validated brief dietary screener that correlates well with a comprehensive food frequency questionnaire. Future studies to test the Mini‐EAT's validity in diverse populations and for development of clinical decision support systems to capture changes over time are needed.
Does NIH funding differ between medical specialties? A longitudinal analysis of NIH grant data by specialty and type of grant, 2011–2020
Schlafly, Andrew , Sebro, Ronnie

Mayo Clinic

BMJ Open | December 30, 2022 | Volume: 12 | Issue: 12 | Pages: e058191

10.1136/bmjopen-2021-058191 | PMID 36585146 Get It

Objectives Differences in National Institutes of Health (NIH) funding between specialties may affect research and patient outcomes in specialties that are less well funded.The aim of this study is to evaluate how NIH funding has been awarded by medical specialty. This study assesses differences and trends in the amount of funding, by medical specialty, for the years 2011–2020, via a retrospective analysis of data from the NIH RePORTER (Research Portfolio Online Reporting Tools Expenditures and Results). Study design Longitudinal cross-sectional study Setting NIH RePORTER data from 2011 to 2020 for awarded NIH grants (F32, T32, K01, K08, K23, R01, R03, R21, U01, P30) in the following medical specialties: anaesthesiology, dermatology, emergency medicine, family medicine, internal medicine, neurology, neurosurgery, obstetrics and gynaecology, ophthalmology, orthopaedic surgery, otolaryngology, pathology, paediatrics, physical medicine and rehabilitation, plastic surgery, psychiatry, radiation-diagnostic/oncology, surgery, and urology. Participants NIH grant awardees for the years 2011-2020 Intervention None Primary and secondary outcome measures The following measures were studied: (1) number of grants by specialty, (2) number of grants per active physician in each specialty, (3) total dollar amount of grants by specialty, (4) total dollar amount of grants per active physician in each specialty and (5) mean dollar amount awarded by specialty for each grant type. We investigated whether any of these measures varied between medical specialties. Results In general, internal medicine/medicine, psychiatry, paediatrics, pathology and neurology received the most grants per year, had the highest number of grants per active physician, had the highest total amount of funding and had the highest amount of funding per active physician, whereas fields like emergency medicine, plastic surgery, orthopaedics, and obstetrics and gynaecology had the lowest. The mean dollar amount awarded by grant type differed significantly between specialties (p value less than the Bonferroni-corrected alpha=0.00029). Conclusions NIH funding varies significantly between medical specialties. This may affect research progress and the careers of scientists and may affect patient outcomes in less well funded specialties.
Reduction of New Heterotopic Ossification ( HO ) in the Open‐Label , Phase 3 MOVE Trial of Palovarotene
Pignolo, Robert J. , Mukaddam, Mona Al , Baujat, Geneviève , Berglund, Staffan K. , Cheung, Angela M. , Cunto, Carmen De , Delai, Patricia , Haga, Nobuhiko , Keen, Richard , Mancilla, Edna E. , Marino, Rose , Strahs, Andrew, Cheung, Angela M , Hsiao, Edward C. , Brown, Matthew , Kannus, Pekka , Sang, Kim‐Hanh Le Quan , Kaplan, Frederick S.

Mayo Clinic

Journal of Bone and Mineral Research | December 30, 2022 | Volume: 38 | Issue: 3 | Pages: 381-394

10.1002/jbmr.4762 | PMID 36583535 Get It

ABSTRACT Fibrodysplasia ossificans progressiva (FOP) is an ultra‐rare, severely disabling genetic disorder of progressive heterotopic ossification (HO). The single‐arm, open‐label, phase 3 MOVE trial (NCT03312634) assessed efficacy and safety of palovarotene, a selective retinoic acid receptor gamma agonist, in patients with FOP. Findings were compared with FOP natural history study (NHS; NCT02322255) participants untreated beyond standard of care. Patients aged ≥4 years received palovarotene once daily (chronic: 5 mg; flare‐up: 20 mg for 4 weeks, then 10 mg for ≥8 weeks; weight‐adjusted if skeletally immature). The primary endpoint was annualized change in new HO volume versus NHS participants (by low‐dose whole‐body computed tomography [WBCT]), analyzed using a Bayesian compound Poisson model (BcPM) with square‐root transformation. Twelve‐month interim analyses met futility criteria; dosing was paused. An independent Data Monitoring Committee recommended trial continuation. Post hoc 18‐month interim analyses utilized BcPM with square‐root transformation and HO data collapsed to equalize MOVE and NHS visit schedules, BcPM without transformation, and weighted linear mixed‐effects (wLME) models, alongside prespecified analysis. Safety was assessed throughout. Eighteen‐month interim analyses included 97 MOVE and 101 NHS individuals with post‐baseline WBCT. BcPM analyses without transformation showed 99.4% probability of any reduction in new HO with palovarotene versus NHS participants (with transformation: 65.4%). Mean annualized new HO volume was 60% lower in MOVE versus the NHS. wLME results were similar (54% reduction fitted; nominal p = 0.039). All palovarotene‐treated patients reported ≥1 adverse event (AE); 97.0% reported ≥1 retinoid‐associated AE; 29.3% reported ≥1 serious AE, including premature physeal closure (PPC)/epiphyseal disorder in 21/57 (36.8%) patients aged <14 years. Post hoc computational analyses using WBCT showed decreased vertebral bone mineral density, content, and strength, and increased vertebral fracture risk in palovarotene‐treated patients. Thus, post hoc analyses showed evidence for efficacy of palovarotene in reducing new HO in FOP, but high risk of PPC in skeletally immature patients. © 2022 The Authors. Journal of Bone and Mineral Research published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research (ASBMR).
Disparities in survival outcomes among Black patients with HPV‐associated oropharyngeal cancer
Baliga, Sujith , Yildiz, Vedat, Konieczkowski, David J. , Grecula, J.C., Blakaj, Dukagjin , Liu, Xuefeng , Gamez, Mauricio E. , Liu, Xuefeng , Mitchell, Darrion , Gogineni, Emile

Mayo Clinic

Journal of Medical Virology | December 30, 2022 | Volume: 95 | Issue: 2 | Pages: No page available

10.1002/jmv.28448 | PMID 36583477 Get It

Abstract Patients with human papillomavirus‐associated oropharyngeal squamous cell carcinoma (HPV‐OPSCC) have a favorable prognosis and excellent overall survival (OS), and studies have demonstrated these findings in cohorts of predominantly White patients. Racial/ethnic (R/E) minorities, particularly Black patients, with head and neck squamous cell carcinoma (HNSCC) have worse survival outcomes compared with White patients. In this study, we aimed to determine if Black patients with HPV‐OPSCC have a similar favorable prognosis to the White population. This was a population‐based retrospective cohort study that analyzed HNSCC patients using the National Cancer Database from 2010 to 2016. We identified patients with Stage I–IV HPV‐ OPSCC who were treated with radiation, surgery, chemotherapy, or a combination of modalities. Patient outcomes were stratified by R/E groups including White Versus Black patients. The main outcome in this study was OS. Analyses for proportions of categorical variables were performed using a χ 2 or Fisher's exact test. Univariate and multivariate time‐to‐event survival analyses were performed using Kaplan–Meier product limit estimates and log‐rank test to test the differences between strata. A Cox proportional hazards regression model was used to assess the association between covariates and risk of death (OS). We identified 9256 OPSCC patients who met inclusion criteria and were treated between 2010 and 2016, of which 7912 were White (85.5%) and 1344 were Black (14.5%). A total of 1727 were HPV‐OPSCC, of which 1598 were White (92.5%) and 129 (7.5%) were Black. By race, the 5‐year OS for White versus Black OPSCC patients was 42% versus 23%, respectively (log‐rank, p < 0.0001). Among HPV‐positive OPSCC patients, the 5‐year OS for White versus Black patients was 65% versus 39% (log‐rank, p < 0.0001). Among HPV‐negative patients, the 5‐year OS for White versus Black patients was 36% versus 13% (log‐rank, p < 0.0001). On multivariate analysis, after accounting for age, sex, insurance status, income, Charlson–Deyo score, receipt of surgery, distance from facility, and total treatment time, Black race trended toward, but was not associated with worse survival. Hazard ratio (HR:1.24, 95% confidence interval [CI] 0.85–1.81, p = 0.255). This national cohort study of OPSCC patients demonstrates that Black patients with HPV‐OPSCC have a poor prognosis and OS similar to HPV‐negative White patients. This may be partly due to socioeconomic barriers such as insurance and income. Further work is needed to better understand the specific drivers of inferior survival outcomes in this specific patient population.
Updates in mechanical thrombectomy
Pierre, Kevin , Perez‐Vega, Carlos , Fusco, Anna , Olowofela, Bankole , Hatem, Rami, Elyazeed, Mohammed, Azab, Mohammed A. , Lucke‐Wold, Brandon

Mayo Clinic

Exploration of Neuroscience | December 30, 2022 | Volume: No volume available | Issue: 2 | Pages: 83-99

10.37349/en.2022.00007 Get It

Stroke is a leading cause of morbidity and mortality. The advent of mechanical thrombectomy has largely improved patient outcomes. This article reviews the features and outcomes associated with aspiration, stent retrievers, and combination catheters used in current practice. There is also a discussion on clinical considerations based on anatomical features and clot composition. The reperfusion grading scale and outcome metrics commonly used following thrombectomy when a patient is still in the hospital are reviewed. Lastly, there are proposed discharge and outpatient follow-up goals in caring for patients hospitalized for a stroke.
It Is in the Eye of the Beholder: Ocular Ultrasound Enhanced Monitoring of Neurotoxicity after CAR-T Cell Therapy
García-Robledo, Juan Esteban , Knox, Molly G., Goodman, Brent P., Patel, B. M. , Castro, Januario E. , Valencia-Sánchez, Cristina , Rosenthal, Allison C, Castro, Januario E , Garcia-Robledo, Juan Esteban , Rosenthal, Allison

Mayo Clinic

Hematology Reports | December 30, 2022 | Volume: 15 | Issue: 1 | Pages: 1-8

10.3390/hematolrep15010001 | PMID 36648879 Get It

Usually used in emergency settings, bedside sonographic measurement of optic nerve sheath diameter can aid in diagnosing elevated intracranial pressure. We report a case of a 26-year-old male hospitalized for CAR T-cell therapy with Axicabtagene Ciloleucel for treatment of relapsed diffuse large B-cell lymphoma, who developed progressive symptoms of immune effector cell-associated neurotoxicity syndrome. Fundoscopic examination suggested the presence of blurred optic disc margins. Bedside ocular ultrasound revealed wide optic nerve sheath diameters and bulging optic discs bilaterally. The patient had a ventriculostomy placed for monitoring and received treatment with steroids and mannitol, as well as tocilizumab. After 7 days in the ICU, the patient recovered with no evidence of long-term neurological deficits.
Intravenous antihypertensive drugs: a double-edged sword?
Twist, Daan J.L. van , Kietselaer, Bas , Kietselaer, Bas L J H, Kietselaer, Bas L J H

Mayo Clinic

Journal of Hypertension | December 30, 2022 | Volume: 41 | Issue: 2 | Pages: 220-222

10.1097/hjh.0000000000003344 | PMID 36583349 Get It

Sleep fragmentation during rapid eye movement sleep and hypertension in obstructive sleep apnea
Zhang, Ye , Yang, Linghui , Covassin, Naima , Tang, Xiangdong , Tang, Xiangdong , Ren, Rong , Shi, Yuan

Mayo Clinic

Journal of Hypertension | December 30, 2022 | Volume: 41 | Issue: 2 | Pages: 310-315

10.1097/hjh.0000000000003332 | PMID 36583357 Get It

Objective: Sleep fragmentation determined by repetitive arousals from sleep in obstructive sleep apnea (OSA) is associated with hypertension. We aimed to quantify the independent association of arousals during rapid eye movement (REM)/non-rapid eye movement (NREM) sleep with prevalent hypertension. Methods: We included adults with 4 h of total sleep time and at least 30 min of REM sleep obtained from overnight in-laboratory polysomnography. Logistic regression models were fitted to explore the association between arousals during REM/NREM sleep and prevalent hypertension. All models controlled for OSA metrics and arousals during NREM/REM sleep, either by statistical adjustment or by stratification. Results: The sample comprised of 11 643 patients, of which 10 055 were OSA patients. Fully adjusted models demonstrated significant dose-relationships between arousal index during REM sleep (AI-REM) and prevalent hypertension (P trend = 0.002). The higher relative odds of prevalent hypertension were most evident with AI-REM > 40 events/h. In OSA patients with arousal index during NREM sleep (AI-NREM) <15 events/h, every10-unit increase in the AI-REM was associated with 18% higher odds of hypertension (odds ratio, 1.18; 95% confidence interval, 1.11–1.27) in OSA. On the contrary, AI-NREM was not a significant predictor of hypertension in any of the models. Conclusions: Our findings indicate that arousals during REM sleep are associated with prevalent hypertension. This is clinically relevant because treatment of OSA is often limited to the first half of the sleep period leaving most of sleep fragmentation during REM sleep untreated.
Large Cancer Pedigree Involving Multiple Cancer Genes including Likely Digenic MSH2 and MSH6 Lynch Syndrome (LS) and an Instance of Recombinational Rescue from LS
Greer, Stephanie , Wang, Fan , Shin, Gi Won , Lau, Billy T. , Hu, Yajing, Alvarez, Rocio , Hazelett, Dennis J. , Nguyen, Peter , Aguirre, Francesca Paola, Hendifar, Andrew , Balcom, Jessica R. , Leininger, Anna, Fairbank, Beth, Ji, Hanlee P. , Hitchins, Megan P. , Wang, Fan , Alvarez, Rocio , Balcom, Jessica, Hitchins, Megan P , Hazelett, Dennis J , Vogelaar, Ingrid P. , Haraldsdóttir, Sigurdís , Aguirre, Francesca Paola, Guindi, Maha M.

Mayo Clinic

Cancers | December 30, 2022 | Volume: 15 | Issue: 1 | Pages: 228

10.3390/cancers15010228 | PMID 36612224 Get It

Lynch syndrome (LS), caused by heterozygous pathogenic variants affecting one of the mismatch repair (MMR) genes (MSH2, MLH1, MSH6, PMS2), confers moderate to high risks for colorectal, endometrial, and other cancers. We describe a four-generation, 13-branched pedigree in which multiple LS branches carry the MSH2 pathogenic variant c.2006G>T (p.Gly669Val), one branch has this and an additional novel MSH6 variant c.3936_4001+8dup (intronic), and other non-LS branches carry variants within other cancer-relevant genes (NBN, MC1R, PTPRJ). Both MSH2 c.2006G>T and MSH6 c.3936_4001+8dup caused aberrant RNA splicing in carriers, including out-of-frame exon-skipping, providing functional evidence of their pathogenicity. MSH2 and MSH6 are co-located on Chr2p21, but the two variants segregated independently (mapped in trans) within the digenic branch, with carriers of either or both variants. Thus, MSH2 c.2006G>T and MSH6 c.3936_4001+8dup independently confer LS with differing cancer risks among family members in the same branch. Carriers of both variants have near 100% risk of transmitting either one to offspring. Nevertheless, a female carrier of both variants did not transmit either to one son, due to a germline recombination within the intervening region. Genetic diagnosis, risk stratification, and counseling for cancer and inheritance were highly individualized in this family. The finding of multiple cancer-associated variants in this pedigree illustrates a need to consider offering multicancer gene panel testing, as opposed to targeted cascade testing, as additional cancer variants may be uncovered in relatives.
Evaluation of the discrimination and calibration of predictive scores of mortality in ECMO for patients with COVID ‐19
Huespe, Iván , Lockhart, Carolina , Pálizas, Fernando , Colombo, Malena, Romero, María del Pilar, Prado, Eduardo , García, Christian A. Casabella, Heras, Marcos Las , Bisso, Indalecio Carboni , Huespe, Ivan Alfredo , Casabella García, Christian A, Carboni Bisso, Indalecio , Kashyap, Rahul

Mayo Clinic

Artificial Organs | December 30, 2022 | Volume: 47 | Issue: 6 | Pages: 1007-1017

10.1111/aor.14493 | PMID 36582133 Get It

Abstract Background The criteria for the selection of COVID‐19 patients that could benefit most from ECMO organ support are yet to be defined. In this study, we evaluated the predictive performance of ECMO mortality predictive models in patients with COVID‐19. We also performed a cost–benefit analysis depending on the mortality predicted probability. We conducted a retrospective cohort study in COVID‐19 patients who received ECMO at two tertiary care hospitals between March 2020 to July 2021. Materials and Methods We evaluated the discrimination (C‐statistic), calibration (Cox calibration), and accuracy of the prediction of death due to severe ARDS in V‐V ECMO score (PRESERVE), the Respiratory Extracorporeal Membrane Oxygenation Survival Score (RESP) score, and the PREdiction of Survival on ECMO Therapy‐Score (PRESET) score. In addition, we compared the RESP score with Plateau pressure instead of Peak pressure. Results We included a total of 36 patients, 29 (80%) of them male and with a median (IQR) APACHE of 10 (8–15). The PRESET score had the highest discrimination (AUROCs 0.81 [95%CI 0.67–0.94]) and calibration (calibration‐in‐the‐large 0.5 [95%CI −1.4 to 0.3]; calibration slope 2.2 [95%CI 0.7/3.7]). The RESP score with Plateau pressure had higher discrimination than the conventional RESP score. The cost per QALY in the USA, adjusted to life expectancy, was higher than USD 100 000 in patients older than 45 years with a PRESET > 10. Conclusion The PRESET score had the highest predictive performance and could help in the selection of patients that benefit most from this resource‐demanding and highly invasive organ support.